Show simple item record

dc.contributor.authorFishel Ben-Kenan, Rotem*
dc.date.accessioned2018-03-30T17:55:28Z
dc.date.available2018-03-30T17:55:28Z
dc.date.issued2018-03-30
dc.identifier.urihttp://hdl.handle.net/10150/627159
dc.descriptionA Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine.en
dc.description.abstractPurpose and Background: Neuroblastomais the most common pediatric extracranialsolid tumor •50% of patients present with metastatic disease typically involving bone and bone marrow •Despite intensive multimodality therapy, 40% of patients with high-risk neuroblastomawill experience relapse •131I-MIBG is an active salvage agent for relapsed and refractory MIBG-avid disease •It is unknown whether disease progression following 131I-MIBG treatment occurs in previously involved vs. new sites of disease •A better understanding of this pattern may inform the use of consolidative focal therapies following 131I-MIBG administration
dc.language.isoen_USen
dc.publisherThe University of Arizona.en_US
dc.rightsCopyright © is held by the author. Digital access to this material is made possible by the College of Medicine - Phoenix, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.en_US
dc.subjectMIBGen
dc.subject131I-MIBGen
dc.subjectPediatricsen
dc.subject.meshNeuroblastomaen
dc.subject.mesh3-Iodobenzylguanidineen
dc.subject.meshNeoplasm Metastasisen
dc.subject.meshChilden
dc.subject.meshAdolescenten
dc.subject.meshChild, Preschoolen
dc.titleAnatomic Patterns of Relapse and Progression Following Treatment with 131I-MIBG in Metastatic Neuroblastomaen_US
dc.typetext; Electronic Thesisen
dc.contributor.departmentThe University of Arizona College of Medicine - Phoenixen
dc.description.collectioninformationThis item is part of the College of Medicine - Phoenix Scholarly Projects 2018 collection. For more information, contact the Phoenix Biomedical Campus Library at pbc-library@email.arizona.edu.en_US
dc.contributor.mentorPolishchuk, Alexeien
refterms.dateFOA2018-04-26T06:35:59Z
html.description.abstractPurpose and Background: Neuroblastomais the most common pediatric extracranialsolid tumor •50% of patients present with metastatic disease typically involving bone and bone marrow •Despite intensive multimodality therapy, 40% of patients with high-risk neuroblastomawill experience relapse •131I-MIBG is an active salvage agent for relapsed and refractory MIBG-avid disease •It is unknown whether disease progression following 131I-MIBG treatment occurs in previously involved vs. new sites of disease •A better understanding of this pattern may inform the use of consolidative focal therapies following 131I-MIBG administration


Files in this item

Thumbnail
Name:
FishelBenKenanR_Poster.pdf
Size:
1.346Mb
Format:
PDF
Description:
Poster
Thumbnail
Name:
Fishel Ben Kenan_thesis.pdf
Size:
727.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record